Artelo Biosciences presents data on solid dosage form of ART12.11 at CN-CANN24

Artelo Biosciences announced Dr. Andrew Yates presented new pre-clinical data on ART12.11 at the CT-CANN24 conference which is being held May 29-30, 2024 at the Hilton London Canary Wharf in London, UK. The presentation, titled “An Aqueous Suspension of a Novel Cannabidiol: Tetramethylpyrazine Co-crystal, demonstrates a pharmacokinetic profile comparable with Epidiolex in Rats,” highlights the Company’s patented cocrystal of CBD and TMP, ART12.11, in an unoptimized formulation, demonstrated comparable pharmacokinetics of CBD and its metabolites to a mimic of Epidiolex, an FDA approved oral solution of CBD in ethanol and sesame oil used for controlling seizures in orphan childhood disorders with over $845 million in net sales for 2023. Oral solutions are commonly used for treating young children; however, for adolescents and adults a solid dosage form is preferred. A tablet form of ART12.11 is expected to be more attractive than an oral solution given its advantages in precise dosing, storage and transport.